Fukuzawa R, Anaka M R, Heathcott R W, McNoe L A, Morison I M, Perlman E J, Reeve A E
Cancer Genetics Laboratory, Department of Biochemistry, University of Otago, PO Box 56, Dunedin, New Zealand.
J Pathol. 2008 Aug;215(4):377-87. doi: 10.1002/path.2366.
Current models of Wilms tumour development propose that histological features of the tumours are programmed by the underlying molecular aberrations. For example, tumours associated with WT1 mutations arise from intralobar nephrogenic rests (ILNR), concur with CTNNB1 mutations and have distinct histology, whereas tumours with IGF2 loss of imprinting (LOI) often arise from perilobar nephrogenic rests (PLNR). Intriguingly, ILNR and PLNR are found simultaneously in Wilms tumours in children with overgrowth who have constitutional IGF2 LOI. We therefore examined whether the precursor lesions or early epigenetic changes are the primary determinant of Wilms tumour histology. We examined the histological features and gene expression profiles of IGF2 LOI tumours and WT1-mutant tumours which are associated with PLNR and/or ILNR. Two distinct types of IGF2 LOI tumours were identified: the first type had a blastemal-predominant histology associated with PLNR, while the second subtype had a myogenic histology, increased expression of mesenchymal lineage genes and an association with ILNR, similar to WT1-mutant tumours. These ILNR-associated IGF2 LOI tumours also showed signatures of activation of the WNT signalling pathway: differential expression of beta-catenin targets (MMP2, RARG, DKK1) and WNT antagonist genes (DKK1, WIF1, SFRP4). Unexpectedly, the majority of these tumours had CTNNB1 mutations, which are normally only seen in WT1-mutant tumours. The absence of WT1 mutations in tumours with IGF2 LOI indicated that CTNNB1 mutations occur predominantly in tumours arising from ILNR independent of the presence or absence of WT1 mutations. Thus, even though these two classes of tumours with IGF2 LOI have the same underlying predisposing epigenetic error, the tumour histology and the gene expression profiles are determined by the nature of the precursor cells within the nephrogenic rests and subsequent CTNNB1 mutations.
目前的肾母细胞瘤发展模型提出,肿瘤的组织学特征是由潜在的分子异常所编程的。例如,与WT1突变相关的肿瘤起源于叶内肾源性残留(ILNR),与CTNNB1突变同时出现且具有独特的组织学特征,而具有IGF2印记缺失(LOI)的肿瘤通常起源于叶旁肾源性残留(PLNR)。有趣的是,在患有全身性IGF2 LOI的过度生长儿童的肾母细胞瘤中同时发现了ILNR和PLNR。因此,我们研究了前体病变或早期表观遗传变化是否是肾母细胞瘤组织学的主要决定因素。我们检查了与PLNR和/或ILNR相关的IGF2 LOI肿瘤和WT1突变肿瘤的组织学特征和基因表达谱。鉴定出两种不同类型的IGF2 LOI肿瘤:第一类具有与PLNR相关的以胚基为主的组织学特征,而第二种亚型具有肌源性组织学特征,间充质谱系基因表达增加且与ILNR相关,类似于WT1突变肿瘤。这些与ILNR相关的IGF2 LOI肿瘤还显示出WNT信号通路激活的特征:β-连环蛋白靶标(MMP2、RARG、DKK1)和WNT拮抗剂基因(DKK1、WIF1、SFRP4)的差异表达。出乎意料的是,这些肿瘤中的大多数具有CTNNB1突变,而CTNNB1突变通常仅在WT1突变肿瘤中出现。具有IGF2 LOI的肿瘤中不存在WT1突变表明CTNNB1突变主要发生在起源于ILNR的肿瘤中,与WT1突变的存在与否无关。因此,尽管这两类具有IGF2 LOI的肿瘤具有相同的潜在易感性表观遗传错误,但肿瘤组织学和基因表达谱是由肾源性残留内前体细胞的性质以及随后的CTNNB1突变所决定的。